Need help finding what you are looking for?
Contact Us
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1354615
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1354615
CNS Therapeutics
PUBLISHED:
PAGES: 898 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
What`s New?
» Special discussions on the global economic climate and market sentiment
» Coverage on global competitiveness and key competitor percentage market shares
» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass™ research platform
» Complimentary updates for one year
» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Economic Outlook
The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.
The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.
Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global CNS Therapeutics Market to Reach $199 Billion by 2030
The global market for CNS Therapeutics estimated at US$114.9 Billion in the year 2022, is projected to reach a revised size of US$199 Billion by 2030, growing at a CAGR of 7.1% over the period 2022-2030. Neurodegenerative Diseases, one of the segments analyzed in the report, is projected to record 7.7% CAGR and reach US$75.9 Billion by the end of the analysis period. Growth in the Mental Health segment is estimated at 6.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $46.5 Billion, While China is Forecast to Grow at 11% CAGR
The CNS Therapeutics market in the U.S. is estimated at US$46.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$19.9 Billion by the year 2030 trailing a CAGR of 11% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5% and 6.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.
Select Competitors (Total 353 Featured) -
- Abbott Laboratories, Inc.
- AbbVie, Inc.
- Acumen Pharmaceuticals, Inc.
- Alexza Pharmaceuticals
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AC Immune SA
- Addex Therapeutics
- Ache Laboratorios Farmaceuticos SA
- 4D pharma plc
- Acadia Pharmaceuticals, Inc.
- AB Science SA
- ABL Bio, Inc.
- AcelRx Pharmaceuticals
- Aarti Drugs Ltd.
- Abion
Product Code: MCP-1835
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
- Year 2021 in Review and Near-term Outlook
- Prolonged Pandemic, Ukraine-Russia Conflict and Ensuing Economic Disruptions Impact Growth Outlook
- World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2021, 2022 and 2023
- Impact of COVID-19 on CNS Therapeutics Market
- The Cascading Effect of COVID-19 and Alzheimer's Disease
- Increased COVID-19 Morbidity and Mortality
- Impact of COVID-19 Pandemic on Parkinson's Disease and Movement Disorders
- COVID-19 Isolation and Patients with Parkinson's Disease
- Special Role of Telemedicine During COVID-19 Pandemic
- A Brief Overview on Impact of Covid-19 On Patients Suffering from Various Mental Disorders
- Central Nervous System (CNS) Therapeutics: A Prelude
- Global Central Nervous System Therapeutic Market Glimmers with Robust Health
- List of FDA Approved CNS Drugs: 2018-2022
- Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
- Patent Expiries of Leading CNS Drugs: 2008-2022
- Developed Markets to Maintain their Dominance
- Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth
- Neurodegenerative Disease & Mental Health: Lifeline Segments of CNS Therapeutics Market
- CNS Cancer Segment to Post Fastest Growth
- Competition
- CNS Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Recent Market Activity
- MARKET ANALYSIS BY THERAPEUTIC CATEGORY
- Anti-Epilepsy Market
- Disease Overview
- Epilepsy Incidence by Type (2022E): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
- Symptomatic Epilepsy Incidence by Type (2022E): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
- Global Epilepsy Etiology: Percentage Breakdown by Type for 2022E
- Drugs for Epilepsy
- Market for Epilepsy Drugs
- Regional Landscape
- Developing Countries Struggle with Low Treatment Rates
- High Unmet Needs Offer Scope for Market Growth
- Treatment
- Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
- Leading Anti-Epileptic Drugs
- Leading Anti-Epileptic Drugs and Their Mechanism of Action
- Patent Expiries of Major Anti-Epilepsy Drugs
- FDA's New Policy for AED Drugs to Bolster Market Growth
- AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
- Select Currently Available Epilepsy Drugs
- Innovative Drugs Needed for Better Treatment Compliance
- Abounding Potential for NCEs
- A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
- FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
- Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
- Recent Approvals for Childhood Epilepsy
- Review of Anti-Epilepsy Drugs
- Vimpat®
- Keppra®
- Lamictal
- Tegretol®
- Sabril®
- Perampanel
- Zonegran®
- Topamax®
- Trileptal®
- Neurontin®
- Lyrica®
- Depakine®
- Anti-Alzheimer's
- Market Overview
- Global Alzheimer's Prevalence by Age Group
- Alzheimer's Phase III Completed Studies
- Alzheimer's Phase III Ongoing Studies
- Treatment for Alzheimer's
- Select Leading Drugs for Alzheimer's Disease by Drug Category
- Patent Expiries of Leading Alzheimer's Drugs
- Alzheimer's Drugs: A Market Plagued with Failures
- Promising Compounds with Silver Lining
- Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
- Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
- Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
- Elenbecestat's Phase 3 Trials Halted
- Novel Drug Delivery Method to the Brain Discovered
- Alzheimer's Association Provides Grant to Longeveron
- A Review of Select Anti-Alzheimer's Drugs
- Aricept
- Exelon
- Reminyl
- Ebixa
- Namenda
- A Review of the Alzheimer's disease
- Alzheimer's Effect on Brain
- Causes for Alzheimer's
- Who Are at Risk?
- Prevalence of Alzheimer's Disease
- Diagnosis of Alzheimer's
- Anti-Parkinson's
- Market Overview
- Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
- Recent Approvals
- Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
- Xadago - Add-On Therapy for Parkinson's Disease
- NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
- Select Parkinson's Phase III Completed Studies: As of June 2022
- Select Parkinson's Ongoing Phase III Studies: As of June 2022
- Select Anti-Parkinson's Drugs
- Levodopa
- Dopamine Agonists
- Mirapex
- GSK Discontinues Requip for PD and RSL Treatment
- A Review of the Parkinson's Disease
- Prevalence
- Symptoms
- Causes
- Diagnosis
- Anti-Depressants
- Market Overview
- Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
- Anti-Depressant Treatment
- Select Antidepressants Drugs
- Zoloft (Sertraline)
- Cymbalta®
- Prozac (Fluoxetine)
- Effexor (Venlafaxine)
- Paxil
- Wellbutrin (Bupropion)
- Select Pipeline Drugs in Phase III for Depressive Disorders: As of June 2022
- A Review of Depression
- Prevalence of Depression
- Causes of Depression
- Types of Depressive Disorders
- Available Treatment
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
- Lithium Salts
- Working of Antidepressants
- Ranking of Antidepressants in Terms of Efficacy
- Types of Antidepressants
- NMDA Receptor Antagonists
- NMDA Receptor (NMDAR)
- NMDA Receptor Agonists
- Acetylcholinesterase Inhibitors
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Workings of SSRIs
- Safety Levels of SSRI Drugs
- Adverse Effects of SSRI
- Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
- Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
- Multiple Sclerosis (MS)
- List of Approved Drugs for MS
- Patent Expiration Date/Year of the Major MS Drugs
- New Approvals
- Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
- Mavenclad Gains FDA Approval
- Celgene Files NDA for Ozanimod
- Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
- Multiple Sclerosis: Pipeline Analysis
- Select Pipeline Drugs in Phase III for Multiple Sclerosis: As of June 2022
- A Review of Multiple Sclerosis (MS)
- Types of Multiple Sclerosis
- Clinical Subtypes of Multiple Sclerosis (MS)
- Prevalence of MS
- Causes of MS
- Myths Surrounding Multiple Sclerosis
- Symptoms of MS
- Diagnosis of MS
- Insomnia
- Overview
- List of Approved Drugs for Insomnia
- Select Pipeline Drugs for Insomnia: As of June 2022
- Zolpidem
- Eszopiclone
- A Review of Insomnia
- Prevalence of Insomnia
- Therapies for Insomnia
- CNS Pain Management
- Market Overview
- Treatment
- Drugs Indicated for Pain Management
- Regional Overview
- Players
- Combination Therapies Gain Prominence
- Key Trends in Chronic Pain Management
- Neuropathic Pain Management: Market with High Potential
- Select Phase III Ongoing Studies for Neuropathic Pain
- Lyrica's Generics Gain FDA Approval
- Migraine Market: A Core Vertical in CNS Pain Management
- Migraine Care: Select Patent Expiries (2013-2015)
- Migraine Completed Phase III Studies
- Migraine Ongoing Phase III Studies
- Select Pain Management Drugs
- Flupirtine
- Lyrica
- Oxycodone
- Nucynta ER
- Metabotropic Glutamate Receptors (mGluRs)
- New Pain Management Drugs
- Novartis Presents New Data for Aimovig
- Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
- Three New Migraine Drugs Obtain FDA Approval
- Eli Lilly's Emgality Receives FDA Approval
- An Insight into Mental Health Prevalence and Addressal
- Global Prevalence of Mental Health Disorders by Type
- Anti-Psychotics
- Market Overview
- Leading Atypical Antipsychotics for the Treatment of Schizophrenia
- Select Pipeline Drugs in Phase III for Schizophrenia: As of June 2022
- Select Pipeline Drugs in Phase III for Bipolar Disorder: As of June 2022
- Select Anti-Psychotic Drugs
- Zyprexa
- Seroquel
- Abilify
- Clozaril
- Risperdal
- Risperdal® Consta®
- Geodon
- Invega Sustenna
- Saphris
- Latuda
- A Review of Anti-Psychotics
- Indications of Antipsychotics
- An Effective Adjunctive Therapy
- Off-label Uses
- Efficacy - Marred by Lack of Evidence Base
- Types of Antipsychotics
- Difference between Typical and Atypical
- Atypical Antipsychotics Up Against Typicals
- Side Effects of Antipsychotics
- Symptoms of Antipsychotics Withdrawal
- Bipolar Disorder
- Symptoms of Bipolar Disorder
- Mood Episode - A Major Symptom
- Manic Episode Vs Depressive Episode
- Causes of Bipolar Disorder
- Types of Bipolar Disorder
- Co-morbidities of Bipolar Disorder
- Schizophrenia
- Prevalence by Gender
- Symptoms of Schizophrenia
- Causes of Schizophrenia
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Incidence of Neurodegenerative Conditions
- Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
- Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
- Rising Healthcare Expenditure to Boost CNS Therapeutics Market
- World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
- Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
- Growing Middle Class Population in Emerging Regions to Spur the Market
- Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
- Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
- Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
- Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
- Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
- Awareness Campaigns Launched by Pharma Companies to Benefit the Market…
- Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
- New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
- Influx of New Products & Strong Pipeline
- CNS Pharmaceuticals Secures FDA Approval for Protocol Amendment to Trial Targeting GBM Treatment
- Central Nervous System Therapeutics: From Bleak to Bright Outlook
- Novel Drug-Delivery Options
- Advances in Drug Discovery Methods for Rare Diseases
- Market Restraint: Complex Nature of R&D
- Ongoing Research on Psychedelics Substances Pave Way for Ensuring Timely Treatment for Various Mental Illnesses
- Advent of Advanced Disease Pathology and Diagnostics Techniques Facilitate Medical Professionals in Diagnosing Mental Illness at an Earlier Stage
- Introduction of Innovative Technologies Fuel Demand for Biological Medicines
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World CNS Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 3: World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 4: World 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 6: World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 7: World 16-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 9: World Historic Review for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 10: World 16-Year Perspective for Mental Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 12: World Historic Review for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 13: World 16-Year Perspective for Neurovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 15: World Historic Review for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 16: World 16-Year Perspective for Cns Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 18: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 19: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- TABLE 20: World Recent Past, Current & Future Analysis for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 21: World Historic Review for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 22: World 16-Year Perspective for Cns Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- TABLE 23: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 24: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 25: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Market Facts & Figures
- Aging Population: A Strong Demographic Driver
- North American Elderly Population by Age Group (1975-2050)
- The Largest CNS Therapeutics Market Globally
- Patent Expiries of Leading CNS Drugs in the US
- Focus on Select Markets
- Alzheimer's Market
- Anti-depressant Drugs
- Usage of Antidepressants Surges in the US
- Anti-Epilepsy Market
- Epilepsy - A Major Concern for the Healthcare Industry
- A Glance at Epilepsy Statistics
- Anti-Epilepsy Drugs
- The US Epilepsy Market: Patent Expiry of Select Major Drugs
- Epilepsy in Children
- Growing Competition from Generics
- Pain Management Market
- Consumers in the US Seek Different Options for Chronic Pain Management
- Neuropathic Pain Market
- Anti-Psychotic Drugs Market
- Mental Illnesses - Epidemiology
- Facts & Figures
- Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
- Popular Antipsychotic Drugs in the US
- The US Anti-Psychotic Drugs Market by Indication (2022E): Percentage Share Breakdown of Value Sales
- Surging Off-label Prescriptions
- Generics Occupy Front Seat
- Rising Antipsychotic Use among Children - A Cause of Concern
- Market Analytics
- Market Analytics
- TABLE 26: USA Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 27: USA Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 28: USA 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- CANADA
- CNS Diseases: Facts & Figures
- TABLE 29: Canada Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 30: Canada Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 31: Canada 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- JAPAN
- TABLE 32: Japan Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 33: Japan Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 34: Japan 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- CHINA
- China: The Primary Market for CNS Drugs in Asia-Pacific
- Select Anti-Schizophrenia Drugs Available in China
- Other Available CNS Drugs in China
- TABLE 35: China Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 36: China Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 37: China 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- EUROPE
- Market Facts & Figures
- Pain Management Market
- Neuropathic Pain Market Witnesses Foray of Generics
- Anti-Psychotics Market
- Demand for Antipsychotics for Bipolar Disorder Upbeat
- Market Analytics
- TABLE 38: Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 39: Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 40: Europe 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- TABLE 41: Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 42: Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 43: Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- FRANCE
- TABLE 44: France Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 45: France Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 46: France 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- GERMANY
- TABLE 47: Germany Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 48: Germany Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 49: Germany 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- ITALY
- Market Snapshots
- TABLE 50: Italy Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 51: Italy Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 52: Italy 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- UNITED KINGDOM
- NICE Recommendations on CNS Therapeutics
- TABLE 53: UK Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 54: UK Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 55: UK 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- SPAIN
- TABLE 56: Spain Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 57: Spain Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 58: Spain 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- RUSSIA
- TABLE 59: Russia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 60: Russia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 61: Russia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- REST OF EUROPE
- TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 63: Rest of Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 64: Rest of Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- ASIA-PACIFIC
- India & China Offer Significant Growth Opportunities
- Growing Antipsychotics Market in Asia
- TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 66: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 67: Asia-Pacific 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 69: Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 70: Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- AUSTRALIA
- TABLE 71: Australia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 72: Australia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 73: Australia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- INDIA
- TABLE 74: India Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 75: India Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 76: India 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- SOUTH KOREA
- TABLE 77: South Korea Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 78: South Korea Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 79: South Korea 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- REST OF ASIA-PACIFIC
- TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 81: Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 82: Rest of Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- LATIN AMERICA
- TABLE 83: Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 84: Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 85: Latin America 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
- TABLE 86: Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 87: Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 88: Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- ARGENTINA
- TABLE 89: Argentina Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 90: Argentina Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 91: Argentina 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- BRAZIL
- TABLE 92: Brazil Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 93: Brazil Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 94: Brazil 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- MEXICO
- TABLE 95: Mexico Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 96: Mexico Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 97: Mexico 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- REST OF LATIN AMERICA
- TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 99: Rest of Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 100: Rest of Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- MIDDLE EAST
- TABLE 101: Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- TABLE 102: Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 103: Middle East 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
- TABLE 104: Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 105: Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 106: Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- IRAN
- TABLE 107: Iran Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 108: Iran Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 109: Iran 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- ISRAEL
- TABLE 110: Israel Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 111: Israel Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 112: Israel 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- SAUDI ARABIA
- TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 114: Saudi Arabia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 115: Saudi Arabia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- UNITED ARAB EMIRATES
- TABLE 116: UAE Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 117: UAE Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 118: UAE 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- REST OF MIDDLE EAST
- TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 120: Rest of Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 121: Rest of Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
- AFRICA
- TABLE 122: Africa Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- TABLE 123: Africa Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- TABLE 124: Africa 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2023 & 2030
IV. COMPETITION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.